ARCHIVES

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

DCCP Board Approves Concepts For Three New RFAs, Contract Recompetitions

June 4, 1982

In Brief: Cancer Panel To Meet In Seattle, Houston, Chicago; Wisconsin’s Robert Johnson Dies; Goldin Retires

August 27, 1982

White House To Appoint Richard Klausner, Molecular Biologist, As NCI’s 11th Director

July 28, 1995

Brown Needs Decision By March 31; Sander Decline HEW Offer

March 4, 1977

Phase II Study Finds Dasatinib May Overcome ALL Resistance

May 25, 2007

PhRMA’s New Ethics Code Prohibits Trinkets, Dinners; Speaking Fees Still OK.

July 11, 2008